Publication date: Oct 01, 2025
To evaluate whether 9-valent human papillomavirus (HPV9) vaccination is associated with an increased risk of juvenile idiopathic arthritis (JIA), particularly during the coronavirus disease-2019 (COVID-19) pandemic. We conducted a retrospective cohort study using TriNetX U. S. Collaborative Network data from January 1, 2016, to December 31, 2023. Girls aged 9-13 years who received their first HPV9 dose in either the prepandemic (2016-2019) or pandemic (2020-2023) period were matched with unvaccinated controls. Exclusion criteria included previous JIA diagnosis, antirheumatic drug use, or positive rheumatoid factor. Incidence of new-onset JIA was tracked over 8 days to 36 months. Cox regression and Kaplan-Meier survival analysis were used to evaluate hazard ratios (HRs) and JIA-free survival. Among 99,243 vaccinated and 1. 1 million control individuals, HPV9 recipients had a significantly reduced risk of JIA at 36 months in both periods (HR 2016-2019, 0. 207, P
| Concepts | Keywords |
|---|---|
| December | Arthritis |
| Girls | Cohort |
| Papillomavirus | Covid |
| Vaccinated | Evaluate |
| Hpv9 | |
| Idiopathic | |
| Jia | |
| Juvenile | |
| Months | |
| Pandemic | |
| Retrospective | |
| Risk | |
| Survival | |
| Vaccination | |
| Valent |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Juvenile Idiopathic Arthritis |
| disease | MESH | COVID-19 Pandemic |
| pathway | KEGG | Coronavirus disease |